Eich D M, Johnson D E, Hastillo A, Thompson J A, Barnhart G R, Ko D J, Lower R R, Hess M L
Cardiovasc Clin. 1990;20(2):199-211.
The implications of this new aggressive form of coronary disease for the transplant population are obvious. It appears that for the majority of transplant patients we have simply bought some time. We have given them a temporary respite from congestive failure and cardiomyopathy while they surmount the daily challenges imposed by immunosuppression. Clearly, this issue now looms as a major stumbling block toward improving long-term survival. It is no longer enough to simply perform the procedure and submit the patient to the rigors of transplantation, only to obtain 50 percent 5-year survival. We must pay particular attention to the patient postoperatively and make those modifications necessary to improve the individual's risk profile. Moreover, we must continue to concentrate our research efforts on interventions in accelerated coronary disease.
这种新型侵袭性冠心病对移植人群的影响显而易见。看来，对于大多数移植患者而言，我们只是为他们争取了一些时间。在他们克服免疫抑制带来的日常挑战时，我们为他们提供了暂时缓解充血性心力衰竭和心肌病的机会。显然，这个问题现在已成为提高长期生存率的一大绊脚石。仅仅进行手术并让患者经受移植的严峻考验，仅获得50%的5年生存率，这已经不够了。我们必须特别关注患者术后情况，并做出必要调整以改善个体的风险状况。此外，我们必须继续将研究精力集中在对加速性冠心病的干预措施上。
